AzTrials
AzTrials

HypertensionNCT03986931

A Pharmacist Intervention for Monitoring and Treating Hypertension Using Bidirectional Texting

A study testing Experimental: Pharmacist-Bidirectional Texting Group in people with Hypertension, run by Linnea Polgreen at 1 site in United States.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

Bidirectional texting is an effective way to collect home blood pressure (BP) measurements from subjects, but collecting BP measurements and sending them to physicians does not necessarily lead to decreased BP. Pharmacist interventions have been successful in decreasing subject BP. Read more about this study

Who is it for?
Ages 21 to 100 years
Conditions the study is for
Hypertension
What is being tested?
Experimental: Pharmacist-Bidirectional Texting Group
Could I receive a placebo?
No, everyone receives an active treatment
How many people
535 participants
Where
1 siteUnited States
Study dates
25 Feb 2020to 22 Jun 2023
Phase
Interventional
Are there results?
Yes, posted in the registrySummary in the doctors' view

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 21 to 100 years
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Who may be able to join

  • Fluent in English or Spanish
  • Have a clinic measured blood pressure of > or = 145 mmHg and/or > or = 95 mmHg at two previous clinic visits or one previous clinic visit and on the day of enrollment
  • Must be a patient at Family Medicine, River Crossings, Scott Blvd, or Muscatine University of Iowa Clinics
  • Live in a zip code that is scored as a 4-10 on the Rural-Urban Commuting Area codes

Who cannot join

  • Currently pregnant or planning to become pregnant in the next year
  • Upper arm circumference greater than 50 cm (20 in)
  • Prisoner status
  • Unable to provide own informed consent

Trial locations and contacts

1 site in 1 country.

United States1 site
  • University of Iowa Hospitals and Clinics

    Iowa City, Iowa, 52242

Other trials in United States

About this study

Bidirectional texting is an effective way to collect home blood pressure (BP) measurements from subjects, but collecting BP measurements and sending them to physicians does not necessarily lead to decreased BP. Pharmacist interventions have been successful in decreasing subject BP. However, pharmacists are expensive, and in successful interventions, spent a substantial amount of time collecting home BP measurements. In this study, a proven pharmacist intervention will be added to a bidirectional texting program to determine if a combined pharmacist-bidirectional texting intervention is successful at decreasing subject BP and increasing subject BP treatment intensification in a cost-effective manner. This study will be a cluster-randomized, controlled trial of a new intervention.

Read the detailed description

HTN is associated with the greatest attributable risk for mortality among all modifiable risk factors for cardiovascular disease.[1] In 2014, there were approximately 72 million adults (29%) with HTN in the US.[2] Several clinical trials have demonstrated that antihypertensive medications reduce cardiovascular events.[3] For example, even a 5 mm Hg difference in systolic BP (SBP) over 3-5 years can reduce the risk of cardiovascular complications and strokes by 25-30%.[4] Yet, approximately 20% of U.S. adults are unaware of their HTN,[5] and among patients diagnosed with HTN, 47% are uncontrolled.[2] Thus, there is a critical need to effectively treat patients with HTN.

Clinical inertia has been identified as the primary cause for delays in achieving BP control for over 20 years.[6-8] Providers often discount office BP readings that may be falsely elevated due to observer or measurement error and/or the clinical surroundings (e.g., white coat HTN).[9-11] Patients are often seen only once or twice a year which further delays BP control. Furthermore,[8, 12] BP goals are achieved in only 49% of the patients who take anti-hypertensive medications.[5] New approaches for acquiring more BP readings are also needed to better monitor and titrate treatment because a significant proportion of patients on therapy are not adequately controlled despite frequent physician visits.

Home BP measurements, (i.e., having patients take their BP at home), can facilitate the more timely diagnosis of HTN by reducing diagnostic uncertainty. In fact, home measurements are better prognostic indicators of stroke and cardiovascular mortality than clinic measurements,[13-15] are more closely correlated with end-organ damage from HTN than clinic measurements,[16, 17] are cost effective and well-tolerated by patients,[18] and generate BP readings that are at least as reproducible as clinic readings.[19] Home BP measurements, if available, may help physicians overcome barriers related to clinical inertia.[20] However, the data must be followed by action. The researchers have pioneered physician-pharmacist collaborative management (PPCM) that has been shown to decrease clinical inertia and improve BP control.[21, 22] Pharmacists have been embedded within the medical office to perform BP management. The pharmacists are able to assess patients' needs and provide recommendations to physicians regarding treatment changes, providing patients with timely therapy adjustments.[23] However, many medical office leaders are unable to hire clinical pharmacists due to limited resources. Therefore, a "virtual", remote clinical pharmacy service has been developed.[24] Pharmacists were able to obtain electronic medical record (EMR) access at all intervention offices for private physician offices throughout Iowa. While the physicians accepted 95% of the pharmacists' recommendations, the effect on improving BP was modest (manuscript under review). Adding the proposed texting platform with home BP monitoring should markedly improve the potency of our remote, telepharmacy intervention.

This trial exhibits clinical equipoise because, although it is known that texting is an efficient method for obtaining home BP measurements, and that pharmacist interventions to improve BP are cost-effective, it is not known if combining these two interventions will also be cost effective. There are four reasons why this study might not be successful. First, while meta-analyses have found significantly improved BP with pharmacist interventions some studies were not successful.[25] Second, more data does not necessarily mean better data: patients could report false values, BP could be abnormally low or high during the measurement period, or the data could be ignored. Third, even better data might not lead to better outcomes: data could be ignored by pharmacists, physicians or patients; pharmacists' recommendations could be ignored by physicians or patients. Fourth, even if the study is effective at improving subject outcomes, it might not be cost effective. Texting might not save as much time as hypothesized. Thus, further research is needed to address these gaps in knowledge.

There is a critical need for an easy-to-use, cost-effective, mobile health (m-health) approach to assist patients and healthcare providers with screening, diagnosis, and monitoring of HTN. Small medical offices and those located in poor or rural areas are unable to operationalize team-based care with pharmacists. The researchers have overcome this barrier with the use of a remote clinical pharmacy services. Coronary heart disease deaths could be reduced by 15-20% and stroke deaths by 20-30% if this intervention effectively improves BP and is implemented more widely in primary care offices.

The goal of this proposal is to evaluate whether a scalable, short messaging service (SMS) approach combined with a pharmacist-based intervention improves BP management cost effectively. To achieve this objective, the following specific aims are proposed:

  1. Determine if mean BP 12 months after the intervention decreases more for the intervention group than the control group. The working hypothesis is that those in the pharmacist-intervention group will achieve larger BP decreases than those in the control group.
  2. Determine if the intervention leads to more intensification of therapy than in the control group. The working hypothesis is that subjects in the pharmacist-intervention group will have more treatment changes than those in the control group.
  3. Determine the cost effectiveness of the intervention. The working hypothesis is that the intervention will be cost effective when compared to the control group.
Conditions
Hypertension
Being tested
Experimental: Pharmacist-Bidirectional Texting Group, Active Comparator: Control Group
Medical subject headings
Hypertension

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Experimental: Pharmacist-Bidirectional Texting GroupOther

    The goal of this intervention is to determine if bidirectional texting and pharmacist monitoring will improve blood pressure control.

  • Active Comparator: Control GroupOther

    This group will receive bidirectional texting, but no pharmacist monitoring.

Study groups in NCT03986931
Study groupRoleWhat they receive
Pharmacist-Bidirectional Texting GroupExperimentalPatients enrolled in the Pharmacist-Bidirectional Texting Group will return 7 morning and 7 evening blood pressure measurements via text message. The report will be shared with a pharmacist who will monitor them for 12 months. The pharmacist will have access to their entire medical record and will provide support and education via text messaging, email, or phone calls, whichever is preferred by the patient. The pharmacist will develop a care plan and make recommendations to the physician through the electronic medical record to quickly adjust therapy to improve control. They will also recommend laboratory testing if indicated. They will have contact with the patient every 2-3 weeks while blood pressure is uncontrolled, and at least every 2 months when it is controlled. The pharmacist will track all recommendations made to physicians and whether or not they were implemented, modified, or rejected.
Receives: Other: Experimental: Pharmacist-Bidirectional Texting Group
Control GroupActive comparatorPatients randomized to the control group will also return 7 morning and 7 evening blood pressure measurements. The report will be shared with a pharmacist who will call the patient to discuss the measurements and possibly recommend follow up with a physician, but no other pharmacist intervention or monitoring will occur during the 12 months.
Receives: Other: Active Comparator: Control Group

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Difference in Change in Systolic Blood Pressure- 12 Months

    The difference between the groups in the change from baseline to 12 months in systolic blood pressure in mm Hg.

    Measured: 12 months

Secondary outcomes (3)
  1. Difference in Change in Diastolic Blood Pressure- 12 Months

    The difference between the groups in the change from baseline to 12 months in diastolic blood pressure in mmHg.

    Measured: 12 months

  2. Number of Medication Changes From 6 to 12 Months

    Total number of medication changes (i.e., dose, discontinuation, initiation, etc.) from 6 months to 12 months as documented in the medical record.

    Measured: 12 months

  3. Dollars Spent Per Patient for 12 Month Bidirectional Texting/Pharmacist Intervention

    Total cost of medications, time spent by research staff, and clinics visits per patient from baseline.

    Measured: 12 months

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted14 Jun 2019
  2. Study start25 Feb 2020
  3. Primary completion22 Jun 2023
  4. Study completion22 Jun 2023

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Treatment
Allocation
Randomised
Intervention model
Parallel groups
Masking
Single blind
Who is masked
Investigator
Enrolment
535 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT03986931
Sponsor's protocol ID
BP Texting and Pharmacist
Other IDs
R61HL144880
Status last verified
Dec 2024
First submitted
10 Jun 2019
Last updated
22 Jan 2025
Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
No

Publications

  • Palmer MJ, Machiyama K, Woodd S, Gubijev A, Barnard S, Russell S, Perel P, Free C. Mobile phone-based interventions for improving adherence to medication prescribed for the primary prevention of cardiovascular disease in adults. Cochrane Database Syst Rev. 2021 Mar 26;3(3):CD012675. doi: 10.1002/14651858.CD012675.pub3.

    PubMed 33769555
  • Polgreen LA, Carter BL, Polgreen PM, Snyder PM, Sewell DK, Bayman EO, Francis SL, Simmering JE, Parker C, Finkelstein R. A pharmacist intervention for monitoring and treating hypertension using bidirectional texting: PharmText BP. Contemp Clin Trials. 2020 Nov;98:106169. doi: 10.1016/j.cct.2020.106169. Epub 2020 Oct 7.

    PubMed 33038500

Questions about this trial

What is this clinical trial studying?

A study testing Experimental: Pharmacist-Bidirectional Texting Group in people with Hypertension, run by Linnea Polgreen at 1 site in United States.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 4 inclusion and 4 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 22 Jan 2025. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

Yes. Results are posted in the registry (first posted 22 Jan 2025). A summary is in the For doctors view, and the full results are on ClinicalTrials.gov.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Difference in Change in Systolic Blood Pressure- 12 Months (time frame: 12 months). It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT03986931, which also lists 2 linked publications.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 22 Jan 2025; AzTrials last refreshed its copy on 8 Nov 2026.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in